secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001493152-25-016562
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics prices $5M offering (7.14M shares + warrants at $0.70), partners with TheracosBio on Brenzavvy
--------------------------------------------------------------------------------

- Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.
- Offering closed Sept 29; H.C. Wainwright acted as placement agent, receiving $350K fee and 500K warrants at $0.875.
- Company to use net proceeds for working capital, R&D, and potential acquisitions.
- Strategic collaboration with TheracosBio to distribute diabetes drug Brenzavvy (bexagliflozin) via 6,500+ pharmacies starting Q4 2025.
- Partnership aims to lower patient costs by bypassing PBMs; Q4 rollout expected to generate near-term revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225016562/0001493152-25-016562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225016562/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-016562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer